ReviewNature reviews. Neurology2016
Guillain-Barré syndrome: a century of progress.
Review in Nature reviews. Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 2 syntheses or guidelines pooled it, 198 citations in OpenAlex.
- Guillain Barré syndrome associated with COVID-19- lessons learned about its pathogenesis during the first year of the pandemic, a systematic review.Autoimmunity reviews · 2021Pooled it
- Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.The Cochrane database of systematic reviews · 2020Pooled it
- Update on Selected Adverse Events of Concern Following Immunization With Acellular Pertussis Vaccines, a Narrative Review.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
- Single cell transcriptome profiling of peripheral blood mononuclear cells in Guillain-Barré syndrome patients.Scientific data · 2026Article
- Association between Guillain-Barré syndrome and 7 autoimmune diseases: a mendelian randomization study.BMC neurology · 2026Article
- Cytomegalovirus-Associated Parainfectious Miller Fisher Syndrome Without Anti-GQ1b Antibodies: A Case Report.The Neurohospitalist · 2026Article
- Pyridostigmine Treatment for Pediatric Axonal Guillain-Barré Syndrome.Muscle & nerve · 2026Article
- Incidence of Guillain-Barré Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain).Pharmaceuticals (Basel, Switzerland) · 2026Article
- Patient Outcomes Among Medicare Beneficiaries With Guillain-Barré Syndrome.Journal of the peripheral nervous system : JPNS · 2026Article
- Guillain-Barré syndrome followingFrontiers in immunology · 2026Article
- Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome.Orphanet journal of rare diseases · 2025Article
- Preharvest Control ofMicroorganisms · 2025Review
- Refractory Crohn's disease complicated with Guillain-Barré syndrome: A case report.World journal of clinical cases · 2025Article
- Article
- Critical insights for intensivists on Guillain-Barré syndrome.Annals of intensive care · 2025Review
- Clinical characteristics of Guillain-Barré syndrome in Shenzhen: a retrospective study.BMC neurology · 2025Article
- Sequential administration of efgartigimod shortened the course of Guillain-Barré syndrome: a case series.Therapeutic advances in neurological disorders · 2025Article
- Evolving understanding of Guillain-Barré syndrome pathophysiology and the central role of the classical complement pathway in axonal injury.Frontiers in neurology · 2025Article
- Predictors of the Short-Term Outcomes of Guillain-Barré Syndrome: Exploring Electrodiagnostic and Clinical Features.Brain and behavior · 2025Article
- Mycoplasma pneumoniae-Triggered Guillain-Barré Syndrome in Children: Two Case Reports of Different ICU Presentations.Cureus · 2024Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts - novel findings that identified the disease we now know as Guillain-Barré syndrome (GBS). 100 years on, we have made great progress with the clinical and pathological characterization of GBS. Early clinicopathological and animal studies indicated that GBS was an immune-mediated demyelinating disorder, and that severe GBS could result in secondary axonal injury; the current treatments of plasma exchange and intravenous immunoglobulin, which were developed in the 1980s, are based on this premise. Subsequent work has, however, shown that primary axonal injury can be the underlying disease. The association of Campylobacter jejuni strains has led to confirmation that anti-ganglioside antibodies are pathogenic and that axonal GBS involves an antibody and complement-mediated disruption of nodes of Ranvier, neuromuscular junctions and other neuronal and glial membranes. Now, ongoing clinical trials of the complement inhibitor eculizumab are the first targeted immunotherapy in GBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.